Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07266831 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotableLead sponsor: Merck Sharp & Dohme LLC to Merck Sharp & Dohme LLCPrimary endpoints: details revised at 2 of 6 entries · Primary completion moved earlier from Mar 21, 2029 to Feb 1, 2029 · Completion pushed from Apr 3, 2030 to Dec 18, 2031 · 4 moreShow 7 more changesShow less
Primary endpoints: details revised at 2 of 6 entries
Primary completion moved earlier from Mar 21, 2029 to Feb 1, 2029
Completion pushed from Apr 3, 2030 to Dec 18, 2031
Interventions: BIC/FTC/TAF (Drug), ISL (Drug), ISL/ULO (Drug), Placebo for BIC/FTC/TAF (Drug), Placebo to ISL/ULO (Drug), ULO (Drug) to BIC/FTC/TAF (Drug), ISL (Drug), ISL/ULO (Drug), Placebo for BIC/FTC/TAF (Drug), Placebo to ISL/ULO (Drug), ULO (Drug)
Eligibility criteria expanded, about 9 words
Secondary endpoints: details revised at 18 of 24 entries
Site details revised at 4 of 55 sites
MinorRe-verified, no change to tracked fieldsv23
MinorSite details revised at 1 of 55 sitesv22
MinorSite details revised at 2 of 55 sitesv21
MinorStudy sites: 56 to 55v20
Show 2 earlier versionsHide 2 earlier versions
MinorStudy sites: 55 to 56v19
MinorStudy sites: 53 to 55v18
MinorTrial sites expanded: 49 → 53 locationsv17
MinorStudy sites: 47 to 49v16
MinorTrial sites expanded: 42 → 47 locationsv15
MinorTrial sites expanded: 34 → 42 locationsv14
MinorTrial sites expanded: 31 → 34 locationsv13
MinorStudy sites: 29 to 31v12
MinorStudy sites: 24 to 29Primary completion date: Apr 12, 2029 to Mar 21, 2029 · Completion date: Apr 25, 2030 to Apr 3, 2030v11Show 2 more changesShow less
Primary completion date: Apr 12, 2029 to Mar 21, 2029
Completion date: Apr 25, 2030 to Apr 3, 2030
MinorStudy sites: 23 to 24v10
MinorStudy sites: 21 to 23Primary completion date: Oct 5, 2029 to Apr 12, 2029v9Show 1 more changeShow less
Primary completion date: Oct 5, 2029 to Apr 12, 2029
MinorStudy sites: 19 to 21v8
MinorStudy sites: 14 to 19v7
MinorStudy sites: 12 to 14v6
MinorStudy sites: 5 to 12v5
MinorStudy sites: 4 to 5v4
MinorStudy sites: 1 to 4Start date changed from estimate of Jan 14, 2026 to Dec 18, 2025v3Show 1 more changeShow less
Start date changed from estimate of Jan 14, 2026 to Dec 18, 2025
NotableTrial status: Not Yet Recruiting to RecruitingStudy sites: 0 to 1v2Show 1 more changeShow less
Study sites: 0 to 1
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Researchers are looking for new ways to treat HIV-1 (Human Immunodeficiency Virus Type 1). The usual (standard) treatment for HIV-1 is antiretroviral therapy (ART), which includes taking medicines to lower the amount of HIV-1 in the body. Standard ART helps people live longer, but people must take up to 3 medicines up to twice a day. Standard ART may also cause other health problems. Researchers want to know if a study ART works as well as a standard ART to treat HIV-1. The study ART combines 2 medicines, islatravir and ulonivirine, and is taken once a week. The goals of this study are to learn: 1) If the study ART works as well as a standard ART to treat HIV-1, and 2) About the safety of the study ART and if people tolerate it compared to a standard ART.